LinkedIn

 آمار

تعداد نشریات21
تعداد شماره‌ها1,276
تعداد مقالات11,673
تعداد مشاهده مقاله82,487,590
تعداد دریافت فایل اصل مقاله121,434,219
Cubillos, Astrid Lorena, Palencia-Sánchez, Francisco, Hernández, Libia Marcela, Riaño-Casallas, Martha Isabel. (1405). Indirect Costs of Non-Communicable Diseases within the Top Ten Causes of Mortality Worldwide: A Systematic Literature Review. سامانه مدیریت نشریات علمی, 51(6), 385-402. doi: 10.30476/ijms.2025.106400.4065
Astrid Lorena Cubillos; Francisco Palencia-Sánchez; Libia Marcela Hernández; Martha Isabel Riaño-Casallas. "Indirect Costs of Non-Communicable Diseases within the Top Ten Causes of Mortality Worldwide: A Systematic Literature Review". سامانه مدیریت نشریات علمی, 51, 6, 1405, 385-402. doi: 10.30476/ijms.2025.106400.4065
Cubillos, Astrid Lorena, Palencia-Sánchez, Francisco, Hernández, Libia Marcela, Riaño-Casallas, Martha Isabel. (1405). 'Indirect Costs of Non-Communicable Diseases within the Top Ten Causes of Mortality Worldwide: A Systematic Literature Review', سامانه مدیریت نشریات علمی, 51(6), pp. 385-402. doi: 10.30476/ijms.2025.106400.4065
Cubillos, Astrid Lorena, Palencia-Sánchez, Francisco, Hernández, Libia Marcela, Riaño-Casallas, Martha Isabel. Indirect Costs of Non-Communicable Diseases within the Top Ten Causes of Mortality Worldwide: A Systematic Literature Review. سامانه مدیریت نشریات علمی, 1405; 51(6): 385-402. doi: 10.30476/ijms.2025.106400.4065

Indirect Costs of Non-Communicable Diseases within the Top Ten Causes of Mortality Worldwide: A Systematic Literature Review

Iranian Journal of Medical Sciences
مقاله 1، دوره 51، شماره 6، شهریور 2026، صفحه 385-402    اصل مقاله (1.29 M)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/ijms.2025.106400.4065
نویسندگان
Astrid Lorena Cubillos1؛ Francisco Palencia-Sánchez1؛ Libia Marcela Hernández2؛ Martha Isabel Riaño-Casallas* 3
1Department of Preventive Medicine, School of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia
2Department of Information Systems, Library Science and Archival Science. Pontificia Universidad Javeriana, Bogotá, Colombia
3Department of Administration and Public Accounting, Economic Sciences Faculty, Universidad Nacional de Colombia, Bogotá, Colombia
چکیده
Background: Chronic non-communicable diseases (NCDs) are a major public health challenge, representing the leading cause of disability and premature mortality worldwide. Beyond direct medical expenses, NCDs generate substantial indirect costs through productivity losses and reduced workforce participation. This study aims to identify the indirect costs reported in scientific literature on NCDs in the economically active population between 2012 and 2022.
Methods: A systematic literature review covering 2012 to 2025 was conducted in PubMed/MEDLINE, PubMed Central (PMC), Embase, Web of Science, and Scopus. Only primary studies in English or Spanish were included, and independent reviews were conducted by two authors.
Results: Of 1980 identified articles, 42 met the inclusion criteria. Indirect costs were mainly represented by productivity losses (absenteeism and presenteeism) and disease burden measured with Disability-Adjusted Life Years (DALYs). The highest volume of research focused on ischemic heart disease, stroke, and chronic obstructive pulmonary disease.
Conclusion: Evidence on indirect costs of NCDs remains limited despite their significant economic and social impact. These conditions reduce both the quality and availability of the workforce and generate high indirect costs. Addressing these challenges requires strategies across all levels of prevention, not only within healthcare systems but also in workplaces, to mitigate the economic burden of NCDs on the economically active population.

تازه های تحقیق

Astrid Lorena, Cubillos (Google Scholar)
Martha Isabel Riaño-Casallas (Google Scholar)

کلیدواژه‌ها
Noncommunicable diseases؛ Cost of illness؛ Systematic review؛ Health care economics and organizations
مراجع
  1. World Health Organization. World health statistics 2020: monitoring health for the SDGs, sustainable development goals. Geneva: WHO; 2020.
  2. Corbett S, Courtiol A, Lummaa V, Moorad J, Stearns S. The transition to modernity and chronic disease: mismatch and natural selection. Nat Rev Genet. 2018;19:419-30. doi: 10.1038/s41576-018-0012-3. PubMed PMID: 29743650.
  3. Hambleton IR, Caixeta R, Jeyaseelan SM, Luciani S, Hennis AJM. The rising burden of non-communicable diseases in the Americas and the impact of population aging: a secondary analysis of available data. Lancet Reg Health Am. 2023;21:100483. doi: 10.1016/j.lana.2023.100483. PubMed PMID: 37065858; PubMed Central PMCID: PMC10090658.
  4. The L. Global health: time for radical change? Lancet. 2020;396:1129. doi: 10.1016/s0140-6736(20)32131-0. PubMed PMID: 33069323; PubMed Central PMCID: PMC7561297.
  5. Andrade CAS, Mahrouseh N, Gabrani J, Charalampous P, Cuschieri S, Grad DA, et al. Inequalities in the burden of non-communicable diseases across European countries: a systematic analysis of the Global Burden of Disease 2019 study. Int J Equity Health. 2023;22:140. doi: 10.1186/s12939-023-01958-8. PubMed PMID: 37507733; PubMed Central PMCID: PMC10375608.
  6. Bennett JE, Stevens GA, Mathers CD, Bonita R, Rehm J, Kruk ME, et al. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392:1072-88. doi: 10.1016/s0140-6736(18)31992-5. PubMed PMID: 30264707.
  7. Shu J, Jin W. Prioritizing non-communicable diseases in the post-pandemic era based on a comprehensive analysis of the GBD 2019 from 1990 to 2019. Sci Rep. 2023;13:13325. doi: 10.1038/s41598-023-40595-7. PubMed PMID: 37587173; PubMed Central PMCID: PMC10432467.
  8. Martinez R, Lloyd-Sherlock P, Soliz P, Ebrahim S, Vega E, Ordunez P, et al. Trends in premature avertable mortality from non-communicable diseases for 195 countries and territories, 1990-2017: a population-based study. Lancet Glob Health. 2020;8:e511-e23. doi: 10.1016/s2214-109x(20)30035-8. PubMed PMID: 32199120.
  9. Bertram M, Banatvala N, Kulikov A, Belausteguigoitia I, Sandoval R, Hennis A, et al. Using economic evidence to support policy decisions to fund interventions for non-communicable diseases. BMJ. 2019;365:l1648. doi: 10.1136/bmj.l1648. PubMed PMID: 31110025; PubMed Central PMCID: PMC6526680.
  10. Nugent R, Bertram MY, Jan S, Niessen LW, Sassi F, Jamison DT, et al. Investing in non-communicable disease prevention and management to advance the Sustainable Development Goals. Lancet. 2018;391:2029-35. doi: 10.1016/s0140-6736(18)30667-6. PubMed PMID: 29627167.
  11. Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204-22. doi: 10.1016/s0140-6736(20)30925-9. PubMed PMID: 33069326; PubMed Central PMCID: PMC7567026.
  12. Cubillos Osorio AL, Palencia Sánchez F, Riaño Casallas M. Tendencias de la evidencia científica de las evaluaciones económicas y las enfermedades no transmisibles: un análisis bibliométrico. Revista Med. 2023;31:59 - 74. doi: 10.18359/rmed.6408.
  13. Kundu J, Chakraborty R. Socio-economic inequalities in burden of communicable and non-communicable diseases among older adults in India: Evidence from Longitudinal Ageing Study in India, 2017-18. PLoS One. 2023;18:e0283385. doi: 10.1371/journal.pone.0283385. PubMed PMID: 36996071; PubMed Central PMCID: PMC10062644.
  14. Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K. The burden and costs of chronic diseases in low-income and middle-income countries. Lancet. 2007;370:1929-38. doi: 10.1016/s0140-6736(07)61696-1. PubMed PMID: 18063029.
  15. Covidence [Internet]. Veritas Health Innovation. c2023. Available from: www.covidence.org
  16. Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ Open. 2016;6:e011458. doi: 10.1136/bmjopen-2016-011458. PubMed PMID: 27932337; PubMed Central PMCID: PMC5168618.
  17. Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13:S31-s4. doi: 10.4103/sja.SJA_543_18. PubMed PMID: 30930717; PubMed Central PMCID: PMC6398292.
  18. Higgins JPT, Morgan RL, Rooney AA, Taylor KW, Thayer KA, Silva RA, et al. A tool to assess risk of bias in non-randomized follow-up studies of exposure effects (ROBINS-E). Environ Int. 2024;186:108602. doi: 10.1016/j.envint.2024.108602. PubMed PMID: 38555664; PubMed Central PMCID: PMC11098530.
  19. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Med. 2022;20:23. doi: 10.1186/s12916-021-02204-0. PubMed PMID: 35022047; PubMed Central PMCID: PMC8753858.
  20. Adarkwah CC, van Gils PF, Hiligsmann M, Evers SM. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharmacoecon Outcomes Res. 2016;16:513-23. doi: 10.1586/14737167.2015.1103185. PubMed PMID: 26588001.
  21. Ford ES, Murphy LB, Khavjou O, Giles WH, Holt JB, Croft JB. Total and state-specific medical and absenteeism costs of COPD among adults aged ≥ 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147:31-45. doi: 10.1378/chest.14-0972. PubMed PMID: 25058738.
  22. Jiang Y, Hesser JE. Using disability-adjusted life years to assess the burden of disease and injury in Rhode Island. Public Health Rep. 2012;127:293-303. doi: 10.1177/003335491212700309. PubMed PMID: 22547860; PubMed Central PMCID: PMC3314073.
  23. McGrath R, Al Snih S, Markides K, Hall O, Peterson M. The burden of health conditions for middle-aged and older adults in the United States: disability-adjusted life years. BMC Geriatr. 2019;19:100. doi: 10.1186/s12877-019-1110-6. PubMed PMID: 30961524; PubMed Central PMCID: PMC6454610.
  24. Vuong TD, Wei F, Beverly CJ. Absenteeism due to Functional Limitations Caused by Seven Common Chronic Diseases in US Workers. J Occup Environ Med. 2015;57:779-84. doi: 10.1097/jom.0000000000000452. PubMed PMID: 26147545; PubMed Central PMCID: PMC4493930.
  25. Ronne-Engström E, Alexanderson K, Friberg E. Sickness absence, disability pension and economic situation after a spontaneous subarachnoid haemorrhage among people of working age: a Swedish longitudinal nationwide cohort study. BMJ Open. 2021;11:e040941. doi: 10.1136/bmjopen-2020-040941. PubMed PMID: 33495252; PubMed Central PMCID: PMC7839850.
  26. Voss M, Ivert T, Pehrsson K, Hammar N, Alexanderson K, Nilsson T, et al. Sickness absence following coronary revascularisation. A national study of women and men of working age in Sweden 1994-2006. PLoS One. 2012;7:e40952. doi: 10.1371/journal.pone.0040952. PubMed PMID: 22848415; PubMed Central PMCID: PMC3404085.
  27. Endo M, Sairenchi T, Kojimahara N, Haruyama Y, Sato Y, Kato R, et al. Sickness absence and return to work among Japanese stroke survivors: a 365-day cohort study. BMJ Open. 2016;6:e009682. doi: 10.1136/bmjopen-2015-009682. PubMed PMID: 26729388; PubMed Central PMCID: PMC4716216.
  28. Kimura K, Nagata T, Ohtani M, Nagata M, Kajiki S, Fujino Y, et al. Cardiovascular and cerebrovascular diseases risk associated with the incidence of presenteeism and the costs of presenteeism. J Occup Health. 2020;62:e12167. doi: 10.1002/1348-9585.12167. PubMed PMID: 32951282; PubMed Central PMCID: PMC7507530.
  29. Mori T, Nagata T, Nagata M, Fujimoto K, Fujino Y, Mori K. Diabetes severity measured by treatment control status and number of anti-diabetic drugs affects presenteeism among workers with type 2 diabetes. BMC Public Health. 2021;21:1865. doi: 10.1186/s12889-021-11913-3. PubMed PMID: 34654398; PubMed Central PMCID: PMC8520264.
  30. Banerjee TK, Dutta S, Ray BK, Ghosal M, Hazra A, Chaudhuri A, et al. Disease burden of stroke in Kolkata, India: derivation of disability-adjusted life years by a direct method. Neuroepidemiology. 2013;41:88-93. doi: 10.1159/000345135. PubMed PMID: 23774662.
  31. Ramachandran R, Jha V. Kidney transplantation is associated with catastrophic out of pocket expenditure in India. PLoS One. 2013;8:e67812. doi: 10.1371/journal.pone.0067812. PubMed PMID: 23861812; PubMed Central PMCID: PMC3701634.
  32. Sudharsanan N, Deshmukh M, Kalkonde Y. Direct estimates of disability-adjusted life years lost due to stroke : a cross-sectional observational study in a demographic surveillance site in rural Gadchiroli, India. BMJ Open. 2019;9:e028695. doi: 10.1136/bmjopen-2018-028695. PubMed PMID: 31699719; PubMed Central PMCID: PMC6858195.
  33. Valsa Jose J, Susan George J, Joseph R, Arun Thomas ET, Philip John G. Out-of-pocket expenditures, catastrophic household finances, and quality of life among hemodialysis patients in Kerala, India. Hemodial Int. 2022;26:569-74. doi: 10.1111/hdi.13037. PubMed PMID: 35761778.
  34. Martínez-Betancur O, Quintero-Cusguen P, Mayor-Agredo L. Estimating disability-adjusted life-years for subtypes of acute ischemic stroke. Rev Salud Publica (Bogota). 2016;18:226-37. doi: 10.15446/rsap.v18n2.31692. PubMed PMID: 28453035.
  35. Adeniji F. Burden of out-of-pocket payments among patients with cardiovascular disease in public and private hospitals in Ibadan, South West, Nigeria: a cross-sectional study. BMJ Open. 2021;11:e044044. doi: 10.1136/bmjopen-2020-044044. PubMed PMID: 34103311; PubMed Central PMCID: PMC8190042.
  36. Aoun M, Helou E, Sleilaty G, Zeenny RM, Chelala D. Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives. BMC Health Serv Res. 2022;22:586. doi: 10.1186/s12913-022-07936-0. PubMed PMID: 35501814; PubMed Central PMCID: PMC9063193.
  37. Catalá-López F, Fernández de Larrea-Baz N, Morant-Ginestar C, Álvarez-Martín E, Díaz-Guzmán J, Gènova-Maleras R. The national burden of cerebrovascular diseases in Spain: a population-based study using disability-adjusted life years. Med Clin (Barc). 2015;144:353-9. doi: 10.1016/j.medcli.2013.11.040. PubMed PMID: 24863563.
  38. Chen CY, Huang YB, Tzu-Chi Lee C. Epidemiology and disease burden of ischemic stroke in Taiwan. Int J Neurosci. 2013;123:724-31. doi: 10.3109/00207454.2013.796552. PubMed PMID: 23594118.
  39. Dierick BJH, Flokstra-de Blok BMJ, van der Molen T, Toledo-Pons N, Román-Rodríguez M, Cosío BG, et al. Work absence in patients with asthma and/or COPD: a population-based study. NPJ Prim Care Respir Med. 2021;31:9. doi: 10.1038/s41533-021-00217-z. PubMed PMID: 33594082; PubMed Central PMCID: PMC78872333.
  40. Dray-Spira R, Herquelot E, Bonenfant S, Guéguen A, Melchior M. Impact of diabetes mellitus onset on sickness absence from work--a 15-year follow-up of the GAZEL Occupational Cohort Study. Diabet Med. 2013;30:549-56. doi: 10.1111/dme.12076. PubMed PMID: 23167285.
  41. Fayet-Moore F, George A, Cassettari T, Yulin L, Tuck K, Pezzullo L. Healthcare Expenditure and Productivity Cost Savings from Reductions in Cardiovascular Disease and Type 2 Diabetes Associated with Increased Intake of Cereal Fibre among Australian Adults: A Cost of Illness Analysis. Nutrients. 2018;10. doi: 10.3390/nu10010034. PubMed PMID: 29301298; PubMed Central PMCID: PMC5793262.
  42. Fernández de Larrea-Baz N, Morant-Ginestar C, Catalá-López F, Gènova-Maleras R, Álvarez-Martín E. Disability-adjusted Life Years Lost to Ischemic Heart Disease in Spain. Rev Esp Cardiol (Engl Ed). 2015;68:968-75. doi: 10.1016/j.rec.2014.11.024. PubMed PMID: 25887346.
  43. Finkelstein EA, Malkin JD, Baid D, Alqunaibet A, Mahdi K, Al-Thani MBH, et al. The impact of seven major noncommunicable diseases on direct medical costs, absenteeism, and presenteeism in Gulf Cooperation Council countries. J Med Econ. 2021;24:828-34. doi: 10.1080/13696998.2021.1945242. PubMed PMID: 34138664.
  44. Frederix I, Vandijck D, Hens N, De Sutter J, Dendale P. Economic and social impact of increased cardiac rehabilitation uptake and cardiac telerehabilitation in Belgium - a cost-benefit analysis. Acta Cardiol. 2018;73:222-9. doi: 10.1080/00015385.2017.1361892. PubMed PMID: 28799460.
  45. Geelhoed-Duijvestijn PH, Pedersen-Bjergaard U, Weitgasser R, Lahtela J, Jensen MM, Östenson CG. Effects of patient-reported non-severe hypoglycemia on healthcare resource use, work-time loss, and wellbeing in insulin-treated patients with diabetes in seven European countries. J Med Econ. 2013;16:1453-61. doi: 10.3111/13696998.2013.852098. PubMed PMID: 24144009.
  46. Gènova-Maleras R, Álvarez-Martín E, Morant-Ginestar C, Fernández de Larrea-Baz N, Catalá-López F. Measuring the burden of disease and injury in Spain using disability-adjusted life years: an updated and policy-oriented overview. Public Health. 2012;126:1024-31. doi: 10.1016/j.puhe.2012.08.012. PubMed PMID: 23062632.
  47. Grisales-Romero H, González D, Porras S. Disability-Adjusted Life Years Due to Mental Disorders and Diseases of the Nervous System in the Population of Medellin, 2006-2012. Rev Colomb Psiquiatr (Engl Ed). 2020;49:29-38. doi: 10.1016/j.rcp.2018.04.003. PubMed PMID: 32081205.
  48. Guariguata L, de Beer I, Hough R, Bindels E, Weimers-Maasdorp D, Feeley FG, 3rd, et al. Diabetes, HIV and other health determinants associated with absenteeism among formal sector workers in Namibia. BMC Public Health. 2012;12:44. doi: 10.1186/1471-2458-12-44. PubMed PMID: 22257589; PubMed Central PMCID: PMC3269375.
  49. Henriques A, Araújo C, Viana M, Laszczynska O, Pereira M, Bennett K, et al. Disability-adjusted life years lost due to ischemic heart disease in mainland Portugal, 2013. Rev Port Cardiol. 2017;36:273-81. doi: 10.1016/j.repc.2016.08.011. PubMed PMID: 28318855.
  50. Iqbal M, Al-Saikhan F. Out-of-pocket healthcare costs of COPD exacerbation episodes: a hidden cost and growing strain on family budgets. J Pharm Res Int. 2020;32:42-8. doi: 10.9734/jpri/2020/v32i530435.
  51. Cicin I, Oksuz E, Karadurmus N, Malhan S, Gumus M, Yilmaz U, et al. Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective. Health Econ Rev. 2021;11:22. doi: 10.1186/s13561-021-00322-2. PubMed PMID: 34173876; PubMed Central PMCID: PMC8233643.
  52. Malinowski KP, Kawalec PP, Moćko P. Indirect costs of absenteeism due to rheumatoid arthritis, psoriasis, multiple sclerosis, insulin-dependent diabetes mellitus, and ulcerative colitis in 2012: a study based on real-life data from the Social Insurance Institution in Poland. Expert Rev Pharmacoecon Outcomes Res. 2016;16:295-303. doi: 10.1586/14737167.2016.1085802. PubMed PMID: 26377953.
  53. Maredza M, Bertram MY, Tollman SM. Disease burden of stroke in rural South Africa: an estimate of incidence, mortality and disability adjusted life years. BMC Neurol. 2015;15:54. doi: 10.1186/s12883-015-0311-7. PubMed PMID: 25880843; PubMed Central PMCID: PMC4396076.
  54. Marthias T, Anindya K, Ng N, McPake B, Atun R, Arfyanto H, et al. Impact of non-communicable disease multimorbidity on health service use, catastrophic health expenditure and productivity loss in Indonesia: a population-based panel data analysis study. BMJ Open. 2021;11:e041870. doi: 10.1136/bmjopen-2020-041870. PubMed PMID: 33597135; PubMed Central PMCID: PMC7893673.
  55. Najafi F, Karami-Matin B, Rezaei S, Khosravi A, Soofi M. Productivity costs and years of potential life lost associated with five leading causes of death: Evidence from Iran (2006-2010). Med J Islam Repub Iran. 2016;30:412. PubMed PMID: 28210577; PubMed Central PMCID: PMC5307621.
  56. Nexø MA, Pedersen J, Cleal B, Bjorner JB. Increased risk of long-term sickness absence, lower rate of return to work and higher risk of disability pension among people with type 1 and type 2 diabetes mellitus: a Danish retrospective cohort study with up to 17 years’ follow-up. Diabet Med. 2020;37:1861-5. doi: 10.1111/dme.14203. PubMed PMID: 31811666.
  57. Ngeugoue FT, Njoumemi Z, Kaze FF. Monthly direct and indirect costs of management of CKD 3 - 5 non-dialysis patients in an out-of-pocket expenditure system: The Case of Yaoundé. Clin Nephrol. 2020;93:100-2. doi: 10.5414/cnp92s117. PubMed PMID: 31397268.
  58. Nhung NT, Long TK, Linh BN, Vos T, Huong NT, Anh ND. Estimation of Vietnam national burden of disease 2008. Asia Pac J Public Health. 2014;26:527-35. doi: 10.1177/1010539513510556. PubMed PMID: 24285779.
  59. Paalanen L, Reinikainen J, Härkänen T, Mattila T, Laatikainen T, Jousilahti P, et al. Comparing data sources in estimating disability-adjusted life years (DALYs) for ischemic heart disease and chronic obstructive pulmonary disease in a cross-sectional setting in Finland. Arch Public Health. 2020;78:58. doi: 10.1186/s13690-020-00439-6. PubMed PMID: 32566225; PubMed Central PMCID: PMC7302348.
  60. Rizk R, Hiligsmann M, Karavetian M, Salameh P, Evers SM. A societal cost-of-illness study of hemodialysis in Lebanon. J Med Econ. 2016;19:1157-66. doi: 10.1080/13696998.2016.1207653. PubMed PMID: 27352200.
  61. Souliotis K, Kousoulakou H, Hillas G, Tzanakis N, Toumbis M, Vassilakopoulos T. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2017;12:1395-400. doi: 10.2147/copd.s132825. PubMed PMID: 28546747; PubMed Central PMCID: PMC5436756.
  62. Zaghloul H, Omar O, Pallayova M, Choudhury S, Taheri S. Factors Associated With Presenteeism at Work in Type 2 Diabetes Mellitus. J Occup Environ Med. 2018;60:1116-9. doi: 10.1097/jom.0000000000001446. PubMed PMID: 30252721.
  63. World Bank [Internet]. World Bank country and lending groups. Washington (DC): World Bank Group; 2025 [cited 2023]. Available from: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups
  64. Patel JG, Nagar SP, Dalal AA. Indirect costs in chronic obstructive pulmonary disease: a review of the economic burden on employers and individuals in the United States. Int J Chron Obstruct Pulmon Dis. 2014;9:289-300. doi: 10.2147/copd.s57157. PubMed PMID: 24672234; PubMed Central PMCID: PMC3964024.
  65. Pedron S, Emmert-Fees K, Laxy M, Schwettmann L. The impact of diabetes on labour market participation: a systematic review of results and methods. BMC Public Health. 2019;19:25. doi: 10.1186/s12889-018-6324-6. PubMed PMID: 30616606; PubMed Central PMCID: PMC6323654.
  66. Tabata A, Yabe H, Katogi T, Yamaguchi T, Mitake Y, Shirai T, et al. Investigation of presenteeism, physical function, and exercise habits in workers with CKD: three case reports with literature review. Ren Replace Ther. 2022;8:16. doi: 10.1186/s41100-022-00403-w. PubMed PMID: 35433032; PubMed Central PMCID: PMC9006519.
  67. Gordois AL, Toth PP, Quek RG, Proudfoot EM, Paoli CJ, Gandra SR. Productivity losses associated with cardiovascular disease: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2016;16:759-69. doi: 10.1080/14737167.2016.1259571. PubMed PMID: 27831848.
  68. Rochmah TN, Rahmawati IT, Dahlui M, Budiarto W, Bilqis N. Economic Burden of Stroke Disease: A Systematic Review. Int J Environ Res Public Health. 2021;18. doi: 10.3390/ijerph18147552. PubMed PMID: 34299999; PubMed Central PMCID: PMC8307880.
  69. Elshahat S, Cockwell P, Maxwell AP, Griffin M, O’Brien T, O’Neill C. The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review. PLoS One. 2020;15:e0230512. doi: 10.1371/journal.pone.0230512. PubMed PMID: 32208435; PubMed Central PMCID: PMC7092970.
  70. Nord E. Disability weights in the Global Burden of Disease 2010: unclear meaning and overstatement of international agreement. Health Policy. 2013;111:99-104. doi: 10.1016/j.healthpol.2013.03.019. PubMed PMID: 23608637.
  71. Egunsola O, Raubenheimer J, Buckley N. Variability in the burden of disease estimates with or without age weighting and discounting: a methodological study. BMJ Open. 2019;9:e027825. doi: 10.1136/bmjopen-2018-027825. PubMed PMID: 31427320; PubMed Central PMCID: PMC6701586.
آمار
تعداد مشاهده مقاله: 197
تعداد دریافت فایل اصل مقاله: 155


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب